RBCC: TheraKine Joint Venture Offers Significant Opportunity in Licensing
NOKOMIS, Fla. -- March 26, 2013
Only days after signing a joint venture agreement with cutting-edge drug
delivery innovators TheraKine, Rainbow BioSciences, the biotech subsidiary of
Rainbow Coral Corp. (OTCBB: RBCC) is working hard to ensure that the
partnership will be a fruitful one. Already, the company is searching for new
targets that would benefit from adding licenses for the drug delivery
protocols TheraKine and RBCC plan to roll out.
The global market for drug delivery technologies is driven by biologics and
medications that can’t be administered effectively through traditional means.
Some experts believe that the worldwide market for the 10 most popular drug
delivery technologies (DDTs) alone could grow to $81.5 billion by 2015.
In order to capture a piece of that growth, RBCC is seeking out healthcare
providers for whom TheraKine’s advanced sustained-release delivery system
could yield significant returns for their clients. TheraKine has developed and
patented novel, tunable technologies with the potential to enable selective,
site-specific drug delivery, allowing for lower drug concentrations and
significantly reducing the risk of drug toxicity.
“Licensing this incredible new platform is going to be one of the key
opportunities to making this a successful partnership,” said RBCC CEO Patrick
Brown. “It’s a top priority for our company moving forward. The potential is
Rainbow BioSciences develops and markets new medical and research technology
innovations to compete in a fast-growing industry alongside companies such as
Bristol Myers Squibb Co. (NYSE:BMY),Biogen Idec Inc. (NASDAQ:BIIB), Abbott
Laboratories (NYSE:ABT) and Valeant Pharmaceuticals International (NYSE:
RBCC is dedicated to delivering new medical research and technologies to a
hungry global marketplace. For more information on RBCC’s initiatives, please
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The Company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visit www.RainbowBioSciences.com. For investment information and
performance data on the Company, please
About TheraKine Ltd.
TheraKine Ltd. is a privately held platform technology company with
laboratories in Berlin (Germany). TheraKine provides innovative reformulation
to enable sustained release for pharmaceutical and biological companies
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.
Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
Press spacebar to pause and continue. Press esc to stop.